Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083577 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00083577 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Arkansas. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00083577, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/MIRT - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 1998-02 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083577
The ClinicalTrials.gov registry entry for NCT00083577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00083577 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00083577 about?
NCT00083577 is a clinical study titled "Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma". The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
What is the current status of trial NCT00083577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 1998-02. Estimated completion is 2005-05.
What conditions does trial NCT00083577 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00083577?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083577?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083577 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.